GlassScriptPhysician profile
David L Siegel
NPI 1104820182
$1,778.51
in general payments reported to CMS, 2019-2025
23 companies · $49.20 in 2025
The $49.20 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $817 · 2020: $139 · 2021: $262 · 2022: $129 · 2023: $269 · 2024: $113 · 2025: $49.20.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $432.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $431.67 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $314.96 | 2019-2023 | Ubrelvy, Skyrizi, Rinvoq |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $310.06 | 2019-2021 | |
| Gilead Sciences, INC. | $249.26 | 2019-2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $196.68 | 2019-2022 | |
| Glaxosmithkline, LLC. | $85.52 | 2019-2021 | |
| Amgen INC. | $82.92 | 2019-2020 | |
| Novo Nordisk INC | $66.14 | 2019-2025 | Wegovy |
| Ferring Pharmaceuticals INC. | $60.57 | 2019-2021 | |
| Celgene Corporation | $57.03 | 2021-2024 | Zeposia |
| Horizon Therapeutics Plc | $44.35 | 2019-2021 | |
| Janssen Biotech, INC. | $41.27 | 2021-2024 | Stelara |
| Abbott Laboratories | $39.40 | 2021-2025 | Proclaim |
| Amarin Pharma, INC. | $32.92 | 2019 | |
| Braintree Laboratories, INC. | $31.84 | 2021-2023 | Sutab, Suflave |
| Allergan, INC. | $30.08 | 2019 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $25.73 | 2024 | Wavewriter Alpha Prime 16 |
| Medtronic, INC. | $18.23 | 2024 | Intellis Adaptivestim |
| Redhill Biopharma INC. | $17.83 | 2021 | |
| Qol Medical, LLC | $17.68 | 2021 | |
| Ultragenyx Pharmaceutical INC. | $16.52 | 2022 | |
| Sanofi Pasteur INC. | $16.18 | 2019 | |
| Nevro Corp. | $12.31 | 2022 | |
| Janssen Pharmaceuticals, INC | $11.03 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Siegel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.